Delivery Order SPE2DB24D2213-SPE2DB25FGXVM
- Not listed
- The Defense Logistics Agency awarded a $3,903.98 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 5, 2025, for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the company's headquarters in Conshohocken, Pennsylvania, with an ultimate completion date of June 6, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $2,108.70. This competitively awarded, non-set-aside contract represents a firm fixed price delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with a ceiling value of $1,054.35. This is a firm fixed price, non-set-aside delivery order executed under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December 2026. The performance...
- The Defense Logistics Agency awarded a $3,734.26 delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This competitive delivery order, which is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), carries a firm fixed price structure and is scheduled for completion by August 15, 2025. The product will be delivered to the company's facilities in...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,537.84 firm fixed price delivery order on July 29, 2025, for NovoLog 100 Unit/mL FlexPen 3mL insulin pens, with an ultimate completion date of July 30, 2025. This non-competitive delivery order was placed against AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and running through December 2026. The product will be delivered to the...
- The Defense Logistics Agency awarded a delivery order valued at $2,427.99 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract, awarded on September 17, 2025, with an ultimate completion date of September 18, 2025, represents a firm fixed-price delivery under a non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical supply chains, particularly supporting...
- The Defense Logistics Agency awarded a $3,795.66 delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of NovoLog 100 Unit/ML FlexPen 3ML insulin pens. This is a firm fixed price delivery order under a competitive, non-set-aside procurement. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of September 4, 2025. This delivery order is a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $4,406.16 delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This is a firm fixed-price delivery order with an ultimate completion date of July 22, 2025, and represents a non-competitive set-aside award. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $5,386.05 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 6, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. This competitive award, which carries an ultimate completion date of August 7, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $4,078.89 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL FlexPen 3mL insulin pens on August 18, 2025, with completion scheduled for August 19, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions...
- SPE2DB24D2213Indefinite Delivery Contract
- SPE2DB24D2213-SPE2DB25FGXVMDelivery Order
The Defense Logistics Agency awarded a $3,016.18 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of NovoLog 100 Unit/mL FlexPen 3mL insulin pens. The contract is a non-set-aside competitive award with an ultimate completion date of September 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical supply vehicle running through December 2026 that serves military healthcare systems globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical federal medical procurement vendor supplying brand-name and generic medications, vaccines, and medical devices across multiple therapeutic domains. The company's portfolio of DLA contracts demonstrates its capability to fulfill diverse pharmaceutical needs ranging from small-value transactions to substantial orders exceeding $45,000. As a child contract under the SPE2DX prime indefinite delivery vehicle, this NovoLog delivery order supports the Defense Health Agency and other military healthcare systems' diabetes management requirements within the broader context of DLA's strategic pharmaceutical prime vendor initiatives.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.0k | 9/11/25 |